Serum - Protection from birth onwards
31 October, 2024 - TIME
TIME "The Best Inventions of 2024" lists University of Oxford and the Serum Institute of India R21/Matrix-M™ Malaria Vaccine as "A Game-Changing Vaccine". Read more...
30 October, 2024 - Press Release
Serum Institute of India Pvt. Ltd. receives positive CHMP opinion from European Medicines Agency (EMA) for, a Novel "SIILTIBCY® – Mycobacterium tuberculosis derived antigens (rdESAT-6 and rCFP-10)", intended as a diagnostic aid for detection of Mycobacterium tuberculosis infection. Read more...
29 August, 2024 - Bloomberg
Adar Poonawalla, CEO of Serum Institute of India, speaks to Bloomberg TV's Haslinda Amin, Reveals Post-Covid Expansion Plans.
31 May, 2024 - TIME Magazine
Serum Institute of India (SII), has been recognized as one of the world's most influential companies by TIME magazine in their 'Most Influential Companies' list for 2024. Read more...
20 May, 2024 - Press Release
Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses, marks a significant milestone with the shipment of its first set of R21/Matrix-M™ malaria vaccine to Africa.Read more...
17 May, 2024 - Press Release
Serum Institute of India (SII), the world's largest vaccine manufacturer, has announced a strategic investment in IntegriMedical, acquiring a 20% stake in the company, to advance Needle-Free Injection System technology.Read more...
03 May, 2024 - Press Release
The collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently approved treatment for non-muscle invasive bladder cancer. SII will manufacture both standard BCG (“sBCG”) & next-generation recombinant BCG (“iBCG”), creating a long-term solution to chronic BCG supply shortage issues.Read more...
25 April, 2024 - The Telegraph
On World Malaria Day, the architects behind the R21/Matrix-M vaccine present their take on the road ahead. Read more...
16 April, 2024 - Press Release
Serum Institute of India Pvt. Ltd (SIIPL), in collaboration with the University of Oxford, is developing a novel solution for Men-B disease, advancing global accessibility to life-saving vaccines. This partnership will deliver lifesaving protection against Men-B through the production of a chimeric protein-based vaccine.Read more...
12 April, 2024 - Press Release
In a landmark collaboration announced today, Serum Institute of India (SII), the world’s largest vaccine manufacturer, has joined forces with Univercells, a Belgian biotech innovator, targeting a dramatic increase in accessibility to personalised cancer care. This partnership aims to bring cutting edge treatment options within reach of millions globally. Read more...
02 April, 2024 - Press Release
Bharat Biotech, a global leader in vaccine and biotherapeutic innovation, also the largest manufacturer of oral polio vaccines, and Bilthoven Biologicals B.V., (BBio), a wholly owned subsidiary of Serum Institute of India Private Limited, based in Netherlands, announced a collaboration today, to further strengthen the production and supply security of Oral Polio Vaccines (OPV). Read more...
14 February, 2024
Dr. Cyrus Poonawalla was awarded the 'Late Dr. Mohan Dharia Nation Building Award' by Sharad Pawar at a award ceremony was held at Balgandharva Auditorium, in the city. The ceremony was graced by former State Chief Minister, Prithviraj Chavan, Dr. Vedprakash Mishra, Chancellor of the Krishna Institute of Medical Sciences, Karad amongst others Read more...
01 February, 2024 - Press Release
Phase 3 Trial data results of The R21/Matrix-M™ vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax’s Matrix-M™ adjuvant has confirmed high efficacy and supported regulatory approvals and licensure in several African countries. Read more...
29 January, 2024
Dr. Cyrus Poonawalla founder and chairman of the Serum Institute of India (SII), was bestowed with a lifetime achievement award by Savitribai Phule Pune University (SPPU). Read more...
23 January, 2024 - Press Release
The world’s largest vaccine manufacturer, the Serum Institute of India Pvt. Ltd (SII), is joining a growing CEPI network of vaccine producers in the Global South to support more rapid, agile, and equitable responses to future public health disease outbreaks. Read more...
02 October, 2023 - Press Release
The R21/Matrix-M™ malaria vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant technology, has been recommended for use by the World Health Organization (WHO) after meeting required safety, quality and effectiveness standards. Read more...
20 August, 2023
Serum Institute of India CEO, Adar Poonawalla received the ‘Udyog Mitra’ award from the Government Of Maharashtra. The ‘Maharashtra Industry Awards’ instituted by the Industry Department of Government of Maharashtra from this year were presented by the Hon'ble Governor of Maharashtra Ramesh Bais in Mumbai. Read more...
12 July, 2023 - Press Release
MenFive®, the first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). Read more...
06 July, 2023
Hon'ble UK Minister of State; Science, Technology & Innovation, George Freeman and UK Trade Commissioner for South Asia, Harjinder Kang along with members of the UK Trade Commission visit Serum Institute Of India and meet with SII CEO Adar Poonawalla and Chairman Dr. Cyrus Poonawalla. Read more...
09 May, 2023
International Society for Pharmaceutical Engineering (ISPE) awards Serum Institute Of India the 2023 Facility of the Year Category Award for Supply Chain and Social Impact. ISPE’s Facility of the Year Awards program is the premier global awards program recognizing innovation and creativity in the pharmaceutical and biotechnology manufacturing industries. Read more...
13 April, 2023 - Press Release
The University of Oxford-developed and Serum Institute of India Pvt Ltd (SIIPL)- manufactured and scaled up R21/Matrix-M™ malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority. Read more...
02 February, 2023
Seth Berkley CEO of Gavi, the Vaccine Alliance visited the Serum Institute Of India (SII) in Pune and met with SII CEO Adar Poonawalla. Read more...
24 January, 2023
On the occasion of India's National Girl Child Day and Cervical Cancer Awareness Month, Serum Institute Of India is pleased to launch the first made-in-India qHPV vaccine 'CERVAVAC' by the hands of our Hon'ble Home Minister Shri Amit Shah. Read more...
19 January, 2023 - Davos 2023
Adar Poonawalla, chief executive of the Serum Institute of India (SII), has spoken about vaccine equity at the World Economic Forum's 2023 Annual Meeting in Davos. Read more...
08 January, 2023
Serum Institute CEO, Adar Poonawalla was conferred with the first Dr. Patangrao Kadam Memorial Award at the inauguration of the Bharti Super Specialty Hospital at Bharti Vidyapeeth, Pune on Sunday 8th January 2023. Read more...
15 December, 2022, Oxford University - News
More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by the Serum Institute of India in just 60 days and doses shipped to Uganda. Read more...
21 September, 2022
Serum Institute of India awarded 'Happiest Workplace Award – 2022' by BW Businessworld and HappyPlus Consulting for focusing towards employee wellbeing and employee happiness as part of its business sustainability and business growth. Read more...
17 September, 2022 - The Indian Express
In regulation, R&D and engagement with private sector, India must internalise lessons learnt, writes Adar Poonawalla, CEO of Serum Institute of India. Read more...
01 September, 2022
Dr. Jitendra Singh, Hon'ble Minister of State of the Ministry of Science and Technology & Earth Sciences announced India’s first indigenously developed Quadrivalent Human Papillomavirus vaccine 'CERVAVAC' for the prevention of cervical cancer. Read more...
24 August, 2022
Serum Institute of India CEO Adar Poonawalla called on Hon'ble Prime Minister Shri. Narendra Modi and congratulated him for his leadership in the fight against the COVID-19 pandemic. Read more...
17 August, 2022
Highlighting 75 years of U.S.-India bilateral relationship and their cooperation on health issues, a delegation from the United States visited the Serum Institute of India. Read more...
23 May, 2022 - CNN Opinion
The time for a Global Pandemic Treaty has never been more urgent, writes Adar Poonawalla, CEO of Serum Institute of India. Read more...
23 May, 2022 - Press Release
The Johns Hopkins Bloomberg School of Public Health awarded the Dean's Medal to Serum Institute of India (SII) Chairman, Dr. Cyrus S Poonawalla for his outstanding work in developing and delivering affordable vaccines and contributing to the Indian biosciences industry. Read more...
07 May, 2022
Adar Poonawalla, CEO of Serum Institute of India receives the Business Leader of The Year award at The Economic Times Awards for Corporate Excellence 2021. Read more...
01 April, 2022
Adar Poonawalla, CEO, Serum Institute of India, was conferred the award for Outstanding Business Leader of the Year at CNBC-TV18's India Business Leaders Awards (IBLA) 2022. Read more...
21 March, 2022
Hon'ble President of India, Shri Ram Nath Kovind confers the Padma Bhushan Award to Dr. Cyrus Poonawalla, Chairman and Managing Director of Serum Institute of India at a civil investiture ceremony held at Rashtrapati Bhavan. Read more...
25 January, 2022
Dr. Cyrus Poonawalla, Chairman and Managing Director of Serum Institute of India to be conferred with the Padma Bhushan Award. Read more...
18 January, 2022
Adar Poonawalla CEO of Serum Institute of India, participates in the World Economic Forum - Davos Agenda Panel Discussion 'Meeting the Challenge of Vaccine Equity'.
Watch the session in full here
08 January, 2022 - India Today
Adar Poonawalla, CEO of Serum Institute of India, speaks to India Today Group Editorial Director Raj Chengappa on the Covid vaccine journey and his plans ahead.
28 December, 2021 - Press Release
Serum Institute of India Pvt. Ltd. and Novavax, Inc receive emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant by the Drugs Controller General of India (DCGI). The vaccine will be manufactured and marketed in India by SII under the brand name COVOVAX™. Read more...
17 December, 2021 - Press Release
World Health Organization (WHO) has granted Emergency Use Listing (EUL) for NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine 'COVOVAX™' with Matrix-M™ adjuvant, for active immunization of individuals 18 years of age and older for the prevention of coronavirus disease 2019 caused by SARS-CoV-2. Read more...
26 November, 2021 - Press Release
Serum Institute of India (SII) today announces it has resumed exports to the international vaccine sharing programme COVAX. Read more...
17 November, 2021
The Philippine Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant. The vaccine will be manufactured and marketed in the Philippines by SII under the brand name COVOVAX™. Read more...
01 November, 2021
The National Agency of Drug and Food Control of the Republic of Indonesia, or Badan Peng was Obat dan Makanan (Badan POM), has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant. It will be manufactured by SII in India and marketed by SII in Indonesia under the brand name COVOVAX™. Read more...
16 September, 2021
Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd. today announced a strategic alliance. Read more...
17 August, 2021
Serum Institute of India (SII) acquires 50% stake of SCHOTT Kaisha to become SCHOTT’s joint venture partner and secure pharma packaging supply. Read more...
13 August, 2021
Dr. Cyrus Poonawalla was conferred with the prestigious Lokmanya Tilak National Award 2021 by Lokmanya Tilak Smarak Trust in Pune. Read more...
06 August, 2021
Novavax and Serum Institute of India file regulatory submissions to the Drugs Controller General of India and to regulatory agencies in Indonesia and Philippines for Novavax' recombinant nanoparticle COVID-19 vaccine. Read more...
30 July, 2021
The Confederation of Indian Industry (CII) has entered into an agreement with Serum Institute of India (SII) to accelerate vaccination in partnership with industry, including healthcare providers. The vaccine drive will target communities in India’s small towns and rural areas to ensure wide coverage. Read more...
30 June, 2021
In conversation with Adar Poonawalla, CEO, Serum Institute of India.
15 February, 2021
World Health Organisation (WHO) grants Emergency Use Listing (EUL) to the AstraZeneca/Oxford COVID-19 vaccine 'COVISHIELD' ChAdOx1-S [recombinant] manufactured by Serum Institute of India (SII). AstraZeneca and SII will now work with the COVAX initiative, enabling equitable global access to its COVID-19 vaccines.Read more...
08 February, 2021
UK delegation led by Secretary of State for International Trade Liz Truss visited the Serum Institute of India. Read more...
04 February, 2021
Serum Institute of India's CEO Adar Poonawalla discusses the need for global harmonization of regulation and vaccine licensing with CNN's Julia Chatterley. View
04 February, 2021
Dynavax and Serum Institute of India are collaborating to develop an adjuvanted tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine candidate adjuvanted with CpG 1018. Read more...
03 February, 2021
UNICEF Executive Director Henrietta Fore stated at briefing on COVAX publishing interim distribution forecast, the conclusion of a long-term supply agreement with the Serum Institute of India for covid-19 vaccines, to access two vaccine products through technology transfer from ASTRAZENECA and NOVAVAX. Read more...
01 February, 2021
Dr. Cyrus Poonawalla Chairman and Managing Director of Serum Institute of India accompanied by the company's Executive Director Natasha Poonawalla called on Vice President of India, Shri M. Venkaiah Naidu at Upa-Rashtrapati Nivas, New Delhi and apprised him about the progress made by the Serum Institute. Read more...
25 January, 2021
As part of its Mission 'Vaccine Maitri', Government of India begins supplying Serum Institute of India's COVISHIELD vaccine to neighbouring and key partner countries. Read more...
15 January, 2021 - NDTV
NDTV takes you inside Serum Institute of India where the COVISHIELD vaccine is being manufactured.View
12 January, 2021 - Serum Institute Of India
'An emotional moment for the team at @SerumInstIndia as the first shipments of COVISHIELD finally leave for multiple locations across India', tweets SII CEO Adar Poonawalla. Read more...
03 January, 2021
COVISHIELD ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) manufactured by the Serum Institute of India has been approved for restricted use in emergency sitation by the Drugs Controller General of India (DCGI). Read more...
30 December, 2020 - India Today TV
India Today TV's Rahul Kanwal visited the Serum Institute of India for a tour of the COVISHIELD vaccine production facility and speaks to CEO Adar Poonawalla about the vaccine. View...
28 December, 2020 - Press Release
Serum Institute of India, announces the launch of India’s first indigenously developed pneumococcal vaccine – PNEUMOSIL; in the presence of Dr. Harsh Vardhan, Minister of Health and Family Welfare today. Read more...
23 December, 2020
Serum Institute of India (SIIPL) has partnered with Dynavax Technologies Corporation a biopharmaceutical company focused on developing and commercializing novel vaccines, and today jointly announced that the first participants have been dosed in the Phase 1 part of the Phase 1/2 clinical trial evaluating SIIPL's vaccine candidate adjuvanted with CpG 1018 to prevent COVID-19. Read more...
14 December, 2020 - Press Release
Codagenix, Inc., and the Serum Institute of India Pvt. Ltd. (SIIPL) today announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK. Read more...
07 December, 2020 - PTI News
Vaccine manufacturing major Serum Institute of India (SII) on Monday said it has applied to Drugs Controller General of India (DCGI) for emergency use authorisation for its COVID-19 vaccine Covishield. Read more...
28 November, 2020, Serum Institute of India
Serum Institute of India Press Conference :7 PM : 28 November 2020.
SII CEO Adar Poonawalla briefs the media.Watch...
28 November, 2020 - Serum Institute of India, Pune.
Hon'ble Prime Minister Shri. Narendra Modi visited the Serum Institute of India to review the Covid-19 vaccine development and met with SII Chairman & Managing Director Dr. Cyrus Poonawalla and CEO Mr. Adar Poonawalla. Read more...
11 November, 2020 - Press Release
Serum Institute of India (SII) and Indian Council of Medical Research (ICMR)announce completion of enrolment of phase 3 clinical trials for COVISHIELD in India. ICMR and SII have further collaborated for clinical development COVOVAX (Novavax) developed by Novavax, USA and upscaled by SII. Read more...
28 October, 2020, NDTV
Adar Poonawalla, CEO of Serum Institute of India in an exclusive interview with NDTV's Vishnu Som. View Interview...
22 October, 2020
PUNE, INDIA, and NEW YORK — OCTOBER 22, 2020 — Today, IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, and Serum Institute of India Pvt. Ltd., a leading manufacturer of vaccines and biologics, announced an agreement with Merck, a leading science and technology company Read more...
29 September, 2020
A further collaboration amongst the Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume, Gavi and the Bill & Melinda Gates Foundation will accelerate the manufacture & delivery of up to 100 million doses of safe & effective COVID-19 vaccines for India & low-and middle-income countries (LMICs) as part of the Gavi COVAX AMC. Read more...
22 September, 2020
Adar Poonawalla explains the timing, challenges & cost of vaccinating the world against covid19. Part 1.View Part 1...
22 September, 2020
Adar Poonawalla explains the timing, challenges & cost of vaccinating the world against covid19. Part 2.View Part 2...
22 September, 2020
Serum Institute has received necessary regulatory approval from the Review Committee on Genetic Manipulation (RCGM) of India's Department of Biotechnology (DBT) for manufacturing Codagenix's COVID-19 vaccine candidate.Read more...
17 September, 2020
Ellen J. MacKenzie, Dean of the Bloomberg School of Public Health and Bloomberg Distinguished Professor in conversation with Dr. Cyrus Poonawalla, Chairman and Managing Director of the Serum Institute of India (SII).View...
16 September, 2020
Novavax, Inc. announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021. Read more...
16 September, 2020
Drugs Controller General of India (DCGI) on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country. Read more...
12 September, 2020
After Astrazeneca resumed Oxford University coronavirus vaccine trial in the United Kingdom, Serum Institute of India said that they will restart the trial in the country once the apex drug regulator allows. Read more...
12 September, 2020
The ongoing randomised controlled clinical trials of the Oxford coronavirus vaccine ChAdOx1 nCoV-19 will resume across all UK clinical trial sites. Read more...
08 September, 2020
SpyBiotech has signed an exclusive global licensing agreement with Serum Institute of India for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19. Read more...
19 August, 2020
Serum Institute of India has initiated the phase 2, 3 clinical trials to evaluate the safety and immune response of coronavirus vaccine candidate on healthy Indian adults after the company got approval from Drugs Controller General of India (DCGI) earlier this month. Read more...
17 August, 2020
The Johns Hopkins Bloomberg School of Public Health announce's Dean’s Medal recipients and has named Cyrus S. Poonawalla for his lifelong work in developing and delivering affordable vaccines. Read more...
11 August, 2020
The Serum Institute of India is preparing to crank out a billion doses. And that's just the beginning.Read more...
07 August, 2020
The Bill & Melinda Gates Foundation said it is backing the world’s largest vaccine maker, Serum Institute of India, to churn out 100 million doses of coronavirus vaccine for poorer countries and price them at less than $3.Read more...
07 August, 2020
Landmark collaboration between the Serum Institute of India (SII), Gavi, and Bill & Melinda Gates Foundation to produce up to 100 million Covid-19 vaccine doses for India and low and middle income Countries as early as 2021 Read more...
06 August, 2020
On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small Read more...
01 August, 2020
Earlier this week, a committee of experts had deferred a decision on the request of SII to start trials and asked the company to amend its protocol for the clinical study Read more...
27 July, 2020
About 6,000 health workers and high-risk individuals including those in close contact of COVID-19 patients have been enrolled in a clinical trial to determine Read more...
23 July, 2020
The Serum Institute Of India is the world largest vaccine maker and is currently partnering on a global mission to make COVID 19 vaccines available for all View...
21 July, 2020, CNN News18
Serum Institute, CEO, Adar Poonawalla speaks to Zakka Jacob on the Oxford Vaccine trails success, third phase of tials in India, and what this means for the world's hopes for a COVID-19 vaccine by 2020 Watch...
21 July, 2020 - ET Online
Adar Poonawalla's Serum Institute of India is one of Astra Zeneca's partners in the search for the vaccine and will potentially be responsible for the mass manufacture of the final product. Read more
20 July, 2020 - LiveMint
Oxford's vaccine is designed to reduce disease and transmission. The potential vaccine is already in large-scale phase III human trials Read more
18 July, 2020 - TheIndianExpress.com
Serum Institute CEO Adar Poonawalla speaks to The Indian Express about their efforts to develop Covid-19 vaccines Read more
15 July, 2020 - LiveMint
The Drug Controller General of India has approved Serum Institute of India Pvt Ltd’s indigenous pneumococcal polysaccharide conjugate vaccine, making it the first indigenously developed vaccine against pneumonia, the government said in a statement. Read more
08 July, 2020 - expresspharma.in
Vaccine maker Serum Institute of India (SII) is hoping to develop a COVID-19 vaccine by the year-end as it is focusing on a “good and safe” product. Read more
17 June, 2020 - LiveMint
Pneumonia is the biggest single killer of children, claiming the life of a child every 39 seconds Read more
10 June, 2020 - ET HealthWorld
Our manufacturing facility is ready and we plan to start production in two months. We are spending more than USD 100 million for this facility Read more
04 June, 2020 - ForbesIndia
Poonawalla is betting big on a Covid-19 vaccine, and preparing for the next possible pandemic Read more
04 June, 2020 - Gavi
World leaders make historic commitments to provide equal access to vaccines for all Read more
05 June, 2020, GAVI - Global Vaccine Summit 2020 - London
The Global Vaccine Summit, hosted by the UK, raises US$ 8.8 billion from 32 donor governments and 12 foundations, corporations and organisations to immunise 300 million children and support the global fight against COVID-19. Read more - GAVI.org
05 June, 2020, Oxford University - News
The University of Oxford in partnership with AstraZeneca has taken the next steps in its commitment to broad and equitable global access to Oxford’s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII). Read more - Oxford University
04 June, 2020, British High Commission - GOV.UK
The UK organised the Global Vaccine Summit 2020 on 4 June, helping secure US$7.4 billion (approximately £6 billion) in funding to support global vaccine supply and immunisation. Read more - gov.uk
03 June, 2020, GAVI.org
On the eve of the Global Vaccine Summit 2020, Serum Institut of India commits to increasing and prioritising HPV vaccine supply to Gavi-supported countries, which have among the highest cervical cancer burdens in the world. Read more - GAVI.org
23 May, 2020, Republic World - Live Tv
In a massive development, a vaccine developed by Pune's Serum Institute of India (SII) is currently being tested at several Pune hospitals like - Ruby Hall, KEM Pune, Jehangir Hospital. Serum is carrying out phase 3 clinical trials of the Recombinant-BCG vaccine in 30 locations across the nation. Read more - Republic World - Live Tv
23 May, 2020, Reuters
If the world is to gain access to a vaccine for COVID-19, there’s a good chance it will pass through the doors of Serum Institute of India. Read more -Reuters
22 May, 2020, ThePrint
At ThePrint's Off The Cuff, Serum Institute of India CEO Adar Poonawalla said efficacy and yields of production can be established only after Phase 3 trials. Read more -ThePrint
22 May, 2020, ThePrint
ThePrint's Editor-in-Chief Shekhar Gupta in conversation with Adar Poonawalla, CEO & Owner of Serum Institute of India. View Interview...
18 May, 2020, DW
The Serum Institute of India (SII) is ramping up production of the Oxford vaccine candidate in anticipation of it passing trials. DW spoke with Serum's CEO Adar Poonawalla about when a vaccine could be ready. Read more -DW
28 April, 2020, NDTV
Adar Poonawalla tells NDTV, Serum Institute of India will start producing the vaccine in May, which should be ready when the Oxford trials end. Watch the interview with Nidhi Razdan - NDTV
24 April, 2020, CNBC-TV18
WHO released a report stating as of April 11th, there are over 70 vaccine candidates are in various stages of trial. UK already started human trials with India's Serum Institute as partner. Watch this CNBC-TV18 special.
22 April, 2020, - India Today
A team of scientists at the University of Oxford are working to produce a vaccine to combat Covid-19. Adar Poonawala's Serum Institute has partnered with the Oxford vaccine project as one of the 7 global institutions behind manufacturing the vaccine. More at: India Today
16 April, 2020, - Maharashtra Times - Marathi
15 April, 2020, - Maharashtra Times - Marathi
02 April, 2020, - CNBC-TV18
Adar Poonawala, CEO of Serum Institute of India, said, “It does take 6-7 years normally to make a vaccine. However, I think we should be able to go into human trials by the end of this year because we are entering into animal studies in about 3 weeks from today. So, that is very encouraging news and I can revise my earlier estimate from 2022 to maybe early next year. Read more at: CNBC-TV18
02 April, 2020, - Economic Times - Health World
Mylab Discovery Solutions Pvt Ltd has partnered with Serum Institute of India’s CEO Adar Poonawalla and Abhijit Pawar, Chairman of APG to scale up the operations of Covid-19 testing kits. Read more at: Economic Times - Health World
01 April, 2020
Serum Institute of India has partnered with American biotechnology firm Codagenixto develop a vaccine against COVID-19, and expects it to be ready by early 2022. View Interview:
17 March, 2020
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. View Video...
19 February, 2020, - The Economic Times
Serum Institute of India (SII) expects to be ready with a vaccine against the novel coronavirus (COVID-19) by early 2022. The vaccine candidate, developed by SII in partnership with American biotechnology firm Codagenix, has progressed to the pre-clinical test phase and we hope to be ready with the vaccine by early 2022," SII CEO Adar Poonawalla said. . Read more at: economictimes.indiatimes.com
20 January, 2020
Ministry of External Affairs, Govt. of India, working closely with Ministry of Health procured a supply of 30,000 doses of Measles/Rubella Vaccines from the Serum Institute of India in respose to a emergency health crisis in the Maldives. Read more at: economictimes.indiatimes.com
20 December, 2019
With a recent approval from the World Health Organization, this high-quality, more affordable vaccine is poised to help more countries access protection against the top cause of deadly childhood pneumonia.more...
20 December, 2019, REFORMA - Mexico [spanish]
The World Health Organization (WHO) certified the first pneumococcal vaccine produced by a manufacturer from a developing country, India.The production of a third pneumococcal conjugate vaccine (PCV), manufactured by the Serum Institute of India, will make it possible to extend immunization against the disease that causes greater infant mortality worldwide.more...
20 December, 2019, Express Healthcare - Indian Express Newspaper
This milestone marks a key step toward improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low- and middle-income countries. Read more at: expresshealthcare.in
19, December, 2019
This milestone marks a key step toward improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low- and middle-income countries.more...
17 November, 2019
Dr. Cyrus Poonawalla was conferred with the Indian Council of Medical Research (ICMR) 'Lifetime Achievement Medal' for his outstanding contribution in healthcare by Bill Gates at the headquarters of ICMR in New Delhi.more...
06 November, 2019
Dr. Cyrus Poonawalla was conferred with the 'Lifetime Achievement Award’ by the Asian Business Leadership Forum (ABLF) at the awards ceremony held on 6th November 2019 in Dubai.more...
09 September, 2019
Serum Institute of India's new plant inaugurated by Hon'ble Union Health Minister Dr. Harsh Vardhan.more...
26 June, 2019
Dr. Cyrus Poonawalla & Mr. Adar Poonawalla interviewed by Rahul Kanwal for India Today's Jab We Met TV Program. View Video...
26 June, 2019
Dr. Cyrus Poonawalla was conferred with the prestigious 'Degree of Doctor of Science, honoris causa' by the University of Oxford, U.K. at a glittering ceremony on June 26, 2019. more...
26 June, 2019
Dr. Cyrus Poonawalla being conferred with the 'Degree of Doctor of Science, honoris causa' by the University of Oxford, U.K. held on June 26, 2019. View Video...
10 December, 2018
Dr. Cyrus Poonawalla, was given the first ever Vaccine Hero award by Gavi, the Vaccine Alliance at Gavi's mid-term review in Abu Dhabi. View Video...
10 December, 2018
Dr Cyrus Poonawalla, Founder of Serum Institute of India (SII) and Chairman of Poonawalla Group, has been given the first ever Vaccine Hero award by Gavi, the Vaccine Alliance. more...
3 June, 2018
The University of Massachusetts Medical School conferred an honorary degree of 'Doctor of Humane Letters' to Dr. Cyrus Poonawalla at the 45th Commencement Activities held in Worcester, U.S.A on June 3rd 2018 more...
June, 2018
The University of Massachusetts Medical School to confer honorary degree to Dr. Cyrus Poonawalla at their 45th Commencement Activities
January, 2018
Conferment of Honorary Degree of Doctor of Letters (D.Litt) to Mr. Adar Poonawalla, CEO of Serum Institute of India by Ajeenkya D Y Patil University more...
November, 2017
Adar Poonawalla, CEO of Serum Institute received the Outsatanding achievement in Business & CSR from CNN-News18's Indian of the Year Awards 2018 more...
31 October, 2017
Serum Institute of India has launched two new products - Rotasiil and Rabishield for rotavirus causing diarrhoea and rabies respectively.more...
Sunday, November 13, 2016
Hon'ble Prime Minister Shri. Narendra Modi visited the Serum Institute of India on Sunday 13th November and met with the Chairman & Managing Director Dr. Cyrus Poonawalla and CEO Mr. Adar Poonawalla. more...
Wednesday, March 04, 2015
Hon'ble Governor of Maharashtra and Chancellor of Universities in the State, Ch Vidyasagar Rao, conferred the Honorary D Litt (Honoris Causa) on Dr. Cyrus Poonawalla for his contributions to public health by manufacturing low cost vaccines. more...
February 2015
Hon'ble Prime Minister, Shri. Narendra Modi being explained by Dr. Cyrus Poonawalla of how Serum Institute of India has contributed worldwide by protecting more than 60% of all children born in 2014. more...
Thursday, February 05, 2015
Dr. Cyrus S. Poonawalla, Chairman and Managing Director, Serum Institute Of India, who pioneered the development of affordable life-saving vaccines and is counted among the largest vaccine manufacturers more...
Wednesday, January 28, 2015
Dr. Cyrus Poonawalla was awarded the CHEMTECH "Lifetime Achievement Award" at the CHEMTECH PBW Leadership & Excellence Awards held on 28th January at Mumbai. more...
Sunday, November 09, 2014
Dr. Cyrus Poonawalla was conferred with the 26th Punyabushan award [Pride of Pune] at the hands of Shri. Sharad Pawar and Shri. N. R. Narayana Murthy at Balgandharva Rangamandir, Pune on Sunday, 9th November 2014. more...
Friday, April 04, 2014
Dr. Cyrus Poonawalla was awarded The Asian Award for the "Business Leader of the Year" at Grosvenor House, London on 4th April 2014. more...
Tuesday, March 04, 2014
Serum Institute of India and Bilthoven Biologicals B.V., The Netherlands, have endeavoured to support the Programme to reach the Global Polio Eradication Initiative [GPEI] Endgame Strategic Plan 2013-2018, by substantially reducing the price of IPV from the prevailing price available in the market, in the recent tender bid with UNICEF. more...
Friday, December 27, 2013
The 10th World Zoroastrian Congress held in Mumbai, India was sponsored by the Serum Institute of India and inaugurated by the President of India, Pranab Mukherjee along with Governor of Maharashtra K. Sankaranarayanan & Dr. Cyrus Poonawalla on 27th December 2013.
Sunday, November 10, 2013
His Royal Highness the Prince of Wales made a private visit to Serum Institute on 10th November 2013 as he was keen to know more about the manufacture of inexpensive yet high quality vaccines that saves the lives of millions of children across the globe. more...
Sunday, November 10, 2013
On their maiden visit to the city, Prince Charles and his wife Camilla Parker Bowles on Sunday made a special stopover at the Serum Institute of India. While the Prince of Wales interacted with scientists and senior officials at the manufacturing facility, plants globally, the Duchess of Cornwall paid a visit to the legendary Poonawalla stud farm. more...
Sunday, November 10, 2013
Dr. Cyrus Poonawalla & Adar Poonawalla gave His Royal Highness Prince of Wales a guided tour of the sprawling Serum Institute Facility.“I’m impressed,” Charles told a gaggle of the institute’s scientists, with whom he engaged in a long conversation. more...
Tuesday, October 29, 2013
The royal couple will be making a special stopover in Pune on November 10 as the personal guests of Cyrus and Adar Poonawalla.
Wednesday, July 4, 2012
Serum Institute of India Ltd. has acquired Bilthoven Biologicals of Netherlands. Through the acquisition, the Serum Institute will get access to technology and expertise for making the Injectable Polio Vaccine (Salk), a unique capability and expertise that is currently possessed by a mere three other vaccine manufacturing plants globally. more...
Sunday, June 3, 2012 PuneMirror
Charity has different faces, and the Microsoft founder wears one defined by humility, found the Poonawallas as they showed him around their vaccine manufacturing facility. more...
Friday, June 1, 2012 The Indian Express
Bill Gates on Thursday visited the Serum Institute of India in Pune, met its CMD Dr. Cyrus Poonawalla whom he referred to as one of the seven vaccine heroes, and evinced interest in several products it is developing. more...
Wednesday, November 2, 2011 Forbes.com
His Serum Institute, says Gates, “makes more vaccines than anybody,” including one for meningitis that sells for a mere 50 cents a dose. These pioneers in breakthrough research (and, in one case, manufacturing) are “fascinating, mythic guys,” says Gates. more...
Friday, August 5, 2011 Serum Institute of India Ltd., Pune
Serum Institute of India Ltd. and Merck have entered into an agreement to develop and commercialize a pneumococcal conjugate vaccine (PCV) for use in the emerging and developing world countries of the world. more...
Tuesday, June 14, 2011 Times of India
Bill Gates & British Prime Minister David Cameron praise Dr. Cyrus Poonawalla & Serum Institute for cutting vaccine prices. Serum offered GAVI the pentavalent vaccine at $1.75 per dose. The vaccine was purchased by GAVI a couple of years ago at more than $3 per dose. more...
Tuesday, June 14, 2011 Sakal Times
Dr. Poonawalla makes far-reaching pledge to Global Alliance for Vaccines and Immunisation (GAVI) in London. Serum Institute has made a commitment to cut the price of its pentavalent vaccine by 60 % - the lowest possible cost in the world. more...
Tuesday, June 14, 2011 DNA
Serum Institute of India Ltd (SII), at an international meet in London, has appealed to big pharma companies and suppliers to follow the principle of ‘philanthropic pricing policy’ for the benefit of underprivileged children across the world.
Poonawalla announced that SII has offered GAVI its pentavalent vaccine at $1.75, which was earlier purchased by GAVI at more than $3 per dose. “This is the most affordable vaccine offered by any manufacturer in the world,” Poonawalla said more...
Monday, June 13, 2011 DNA
The Bill and Melinda Gates Foundation has welcomed the initiative of city-based pharmaceutical giant, Serum Institute of India (SII), to lower the price of its pentavalent vaccine for the developing world and for the United Nations Children’s Fund (Unicef). more...
Monday, June 13, 2011 Indian Express
Dr Cyrus Poonawalla, chief managing director of Serum Institute of India, on Monday urged big pharmaceutical firms to take their lead and offer vaccines at lower prices for saving lives. He was speaking at a pledging conference in London held by the Global Alliance for Vaccines and Immunisation (GAVI). British Prime Minister David Cameron and Bill Gates, co-founder of the Bill and Melinda Gates foundation. more...
Wednesday, September 29, 2010 Sakal Times
The Pan American Health Organization (PAHO) and the Pan American Health and Education Foundation (PAHEF) have presented Dr Cyrus S Poonawalla, with the Award for “Excellence in Inter-American Public Health”, making him the first Indian to get this prestigious honor in Washington DC, USA. Dr. Poonawalla received this award from Dr. Mirta Roses Periago, director of the Pan American Health Organization (PAHO) for his extraordinary contribution to eliminate rubella and congenital rubella syndrome in America. more...
Wednesday, September 29, 2010
Friday, August 14, 2009 DNA Pune
City-based Serum Institute of India has been told to concentrate on the development of the H1N1 vaccine and put the development of H5N1 (avian flu) vaccine on the back burner by the World Health Organisation (WHO). more...
Wednesday, August 5, 2009 DNA Mumbai
Serum Institute of India (SII) in Pune is looking forward to an early date for producing a H1N1 vaccine. more...
Friday, July 31, 2009 Sakal Times Pune
Serum Institute is working on Influenza A H1N1 virus strain to prepare a injectable vaccine to be ready for animal testing in the next two months. more...